<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="404">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01281787</url>
  </required_header>
  <id_info>
    <org_study_id>IEO S365/407</org_study_id>
    <secondary_id>2007-003856-12</secondary_id>
    <nct_id>NCT01281787</nct_id>
  </id_info>
  <brief_title>PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer</brief_title>
  <acronym>PRESAGE</acronym>
  <official_title>Prevention of Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Institute of Oncology</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess whether prophylactic treatment with metoprolol or
      losartan is able to reduce the incidence of atrial fibrillation (AF) in patients undergoing
      thoracic surgery for lung cancer, showing elevated plasma levels in NT probrain natriuretic
      peptide (NT-proBNP), measured in the perioperative period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative atrial fibrillation is one of the most common complication after thoracic
      surgery for lung cancer, with an incidence ranging from 8 to 20% after lobectomy and up to
      42% after pneumonectomy.

      In a recent study we demonstrated that a high perioperative plasma levels of NT-proBNP is
      able to identify patients at risk for AF (incidence of 65%).

      It has also been demonstrated that the renin-angiotensin system may play an important role
      in the pathophysiology of  atrial fibrillation and that angiotensin converting enzyme
      inhibitors (ACEI) and angiotensin II receptor blockers (ARBs) are able to prevent atrial
      fibrillation in patients with heart failure, after myocardial infarction, in hypertensive
      patients and after electrical cardioversion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of postoperative atrial fibrillation</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of NT-proBNP in the days following the start of treatment and post surgery duration  of  hospital stay</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>angiotensin II-receptor blocker</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no preventive treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>beta-adrenergic antagonist</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <other_name>SELOKEN, LOPRESOR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay</description>
    <arm_group_label>Losartan</arm_group_label>
    <other_name>LORTAAN, NEOLOTAN, LOSAPREX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes with age â‰¥ 18 years

          -  Thoracic surgery for lung cancer

          -  Evidence of elevated perioperative NT-proBNP

          -  Written informed consent

        Exclusion Criteria:

          -  Hypersensitivity and / or intolerance to metoprolol or losartan

          -  History of heart failure

          -  Left ventricular ejection fraction &lt;50% measured by echocardiographic techniques
                                                            (Simpson rule)

          -  Permanent atrial fibrillation

          -  Antiarrhythmic therapy

          -  Current therapy with beta-blockers, angiotensin II receptor blockers and
             angiotensin-converting enzyme inhibitors

          -  Systolic blood pressure &lt;95 mmHg

          -  Pregnant and lactating women

        Additional exclusion criteria for therapy with beta-blocker:

          -  History of sick sinus syndrome, evidence of AV-block grade II or greater

          -  Heart rate &lt;65 b / m

          -  History of bronchial asthma, severe bronchopneumopathy, evidence of bronchospasm
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Cardinale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Cardinale, MD</last_name>
    <email>daniela.cardinale@ieo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlo M Cipolla, MD</last_name>
    <email>carlo.cipolla@ieo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>daniela cardinale, MD</last_name>
      <phone>39.02.57489539</phone>
      <email>daniela.cardinale@ieo.it</email>
    </contact>
    <contact_backup>
      <last_name>carlo M cipolla, MD</last_name>
      <phone>39.02.57489539</phone>
      <email>carlo.cipolla@ieo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Daniela Cardinale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 4, 2012</lastchanged_date>
  <firstreceived_date>December 21, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FAP= post-surgery  atrial fibrillation</keyword>
  <keyword>ACEI= angiotensin converting enzyme-inhibitors</keyword>
  <keyword>ARBs= angiotensin II receptor blockers</keyword>
  <keyword>NT-proBNP= brain natriuretic peptide</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Metoprolol succinate</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
